The results demonstrated that in gliomas, low levels of cyclinD2 may be associated with lower glioma grades and longer survival time, and further confirmed that cyclinD2 may act as a positive regulator in tumorigenesis and function as a tumor oncogene in gliomas. This evidence concerns the gene CCND2 and glioma.